Commercial COVID-19 Oral Antivirals Memo

Centers for Medicare & Medicaid Services. (2024). Commercial COVID-19 Oral Antivirals Memo.
This memo provides an update on the status of the transition of Paxlovid and Lagevrio to the commercial market, highlighting the overlap of USG-distributed and commercial products. Information on processing claims for these medications are provided as is a figure that depicts primary Medicare beneficiary coverage pathways for commercial anti-virals for COVID-19.
Rate: Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.